Long-term BMS exec Johanna Mercier joins Gilead as new Chief Commercial Officer
pharmafile | June 7, 2019 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Gilead, appointment, pharma
Gilead Sciences have said Bristol-Myers Squibb exec Johanna Mercier will be the firm’s new Chief Commercial Officer.
In her new role Mercier will join Gilead’s senior leadership team when she takes over the California firm’s commercial operations on July 1.
Mercier, who served with BMS for more than ten years, brings a wealth of experience to the role. The experienced executive holds a degree in Biology from the University of Montreal and an MBA from Concordia University.
Having held leadership positions in locations around the world, Mercier brings with her experience in therapeutic areas including oncology, inflammation and neuroscience from positions in countries including the United Kingdom, France and the United States.
In her most recent position Mercier served as President and Head of BMS’ Large Markets division, which includes the United States, France, Germany and Japan.
“I believe that Johanna has the skills to continue to strengthen our performance and position Gilead for long-term success, building on the great talent I have seen across the organization since joining the company several months ago,” said Daniel O’Day, Chairman and Chief Executive Officer.
“She is a talented leader with a deep understanding of the pharmaceutical industry, across therapeutic markets and geographies, as well as a proven ability to input the commercial perspective into development strategies. I look forward to welcoming her to Gilead and to working closely with her to ensure optimal commercial delivery that puts the needs of patients at the center of all we do.”
Commenting on her own appointment Mericer said: “Gilead is an organization that is deeply committed to bringing forward transformational medicines for patients with serious illnesses. Throughout my career, I have worked to improve care for people with unmet medical needs and I am excited to join a company that shares my commitment to doing what is right for patients – and to advancing and commercialising important new medicines.”
Related Content
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …
Novartis acquires Chinook Therapeutics for $3.5bn
Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …
